nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A3—bipolar disorder	0.252	0.31	CbGaD
Duloxetine—HTR2C—bipolar disorder	0.227	0.28	CbGaD
Duloxetine—SLC6A4—bipolar disorder	0.188	0.232	CbGaD
Duloxetine—HTR2A—bipolar disorder	0.145	0.178	CbGaD
Duloxetine—SLC6A2—locus ceruleus—bipolar disorder	0.00956	0.134	CbGeAlD
Duloxetine—HTR2A—locus ceruleus—bipolar disorder	0.00575	0.0804	CbGeAlD
Duloxetine—SLC6A3—telencephalic ventricle—bipolar disorder	0.00562	0.0786	CbGeAlD
Duloxetine—HTR2C—telencephalic ventricle—bipolar disorder	0.00543	0.076	CbGeAlD
Duloxetine—SLC6A2—autonomic nervous system—bipolar disorder	0.00508	0.0711	CbGeAlD
Duloxetine—NPY1R—adrenal cortex—bipolar disorder	0.00323	0.0452	CbGeAlD
Duloxetine—CYP1A2—urine—bipolar disorder	0.00318	0.0446	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—bipolar disorder	0.00305	0.0427	CbGeAlD
Duloxetine—HTR2A—telencephalic ventricle—bipolar disorder	0.00273	0.0381	CbGeAlD
Duloxetine—HTR2A—urine—bipolar disorder	0.00249	0.0348	CbGeAlD
Duloxetine—SLC6A4—blood plasma—bipolar disorder	0.00246	0.0344	CbGeAlD
Duloxetine—CYP2D6—urine—bipolar disorder	0.00227	0.0317	CbGeAlD
Duloxetine—NPY1R—thyroid gland—bipolar disorder	0.00225	0.0315	CbGeAlD
Duloxetine—NPY1R—nervous system—bipolar disorder	0.00189	0.0265	CbGeAlD
Duloxetine—CYP1A2—blood plasma—bipolar disorder	0.00166	0.0233	CbGeAlD
Duloxetine—NPY1R—brain—bipolar disorder	0.00145	0.0203	CbGeAlD
Duloxetine—HTR6—nervous system—bipolar disorder	0.00133	0.0187	CbGeAlD
Duloxetine—HTR2A—blood plasma—bipolar disorder	0.0013	0.0182	CbGeAlD
Duloxetine—CYP2D6—blood plasma—bipolar disorder	0.00118	0.0166	CbGeAlD
Duloxetine—HTR6—brain—bipolar disorder	0.00102	0.0143	CbGeAlD
Duloxetine—SLC6A3—nervous system—bipolar disorder	0.000797	0.0111	CbGeAlD
Duloxetine—HTR2C—nervous system—bipolar disorder	0.00077	0.0108	CbGeAlD
Duloxetine—SLC6A3—cerebellum—bipolar disorder	0.00075	0.0105	CbGeAlD
Duloxetine—SLC6A4—nervous system—bipolar disorder	0.00073	0.0102	CbGeAlD
Duloxetine—Protriptyline—SLC6A4—bipolar disorder	0.000712	0.185	CrCbGaD
Duloxetine—SLC6A2—nervous system—bipolar disorder	0.000643	0.009	CbGeAlD
Duloxetine—SLC6A3—brain—bipolar disorder	0.000609	0.00852	CbGeAlD
Duloxetine—HTR2C—brain—bipolar disorder	0.000589	0.00824	CbGeAlD
Duloxetine—CYP1A2—thyroid gland—bipolar disorder	0.000588	0.00822	CbGeAlD
Duloxetine—Fluoxetine—HTR2C—bipolar disorder	0.000587	0.152	CrCbGaD
Duloxetine—SLC6A4—brain—bipolar disorder	0.000558	0.00781	CbGeAlD
Duloxetine—SLC6A2—brain—bipolar disorder	0.000491	0.00688	CbGeAlD
Duloxetine—Fluoxetine—SLC6A4—bipolar disorder	0.000486	0.126	CrCbGaD
Duloxetine—Atomoxetine—SLC6A3—bipolar disorder	0.000418	0.108	CrCbGaD
Duloxetine—HTR2A—nervous system—bipolar disorder	0.000386	0.00541	CbGeAlD
Duloxetine—Atomoxetine—HTR2C—bipolar disorder	0.000377	0.0978	CrCbGaD
Duloxetine—Fluoxetine—HTR2A—bipolar disorder	0.000374	0.097	CrCbGaD
Duloxetine—HTR2A—cerebellum—bipolar disorder	0.000364	0.00509	CbGeAlD
Duloxetine—CYP2D6—nervous system—bipolar disorder	0.000352	0.00493	CbGeAlD
Duloxetine—Propranolol—HTR1A—bipolar disorder	0.000348	0.0902	CrCbGaD
Duloxetine—CYP2D6—cerebellum—bipolar disorder	0.000331	0.00463	CbGeAlD
Duloxetine—Atomoxetine—SLC6A4—bipolar disorder	0.000313	0.0811	CrCbGaD
Duloxetine—HTR2A—brain—bipolar disorder	0.000295	0.00413	CbGeAlD
Duloxetine—CYP2D6—brain—bipolar disorder	0.000269	0.00376	CbGeAlD
Duloxetine—Atomoxetine—HTR2A—bipolar disorder	0.00024	0.0623	CrCbGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD5—bipolar disorder	5.39e-05	0.000481	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HTR1A—bipolar disorder	5.32e-05	0.000474	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADM—bipolar disorder	5.29e-05	0.000472	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RGS4—bipolar disorder	5.29e-05	0.000471	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TAC1—bipolar disorder	5.24e-05	0.000467	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NTRK1—bipolar disorder	5.23e-05	0.000467	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD2—bipolar disorder	5.18e-05	0.000462	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—bipolar disorder	5.17e-05	0.000461	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PDE4B—bipolar disorder	5.16e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TACR1—bipolar disorder	5.16e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TSHB—bipolar disorder	5.16e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD5—bipolar disorder	5.15e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD1—bipolar disorder	5.14e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HTR2C—bipolar disorder	5.14e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKR1C4—bipolar disorder	5.14e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DGKH—bipolar disorder	5.12e-05	0.000456	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—S100B—bipolar disorder	5.09e-05	0.000454	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—bipolar disorder	5.06e-05	0.000451	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—RGS4—bipolar disorder	5.05e-05	0.000451	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—bipolar disorder	5.04e-05	0.00045	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ADCY2—bipolar disorder	5.03e-05	0.000448	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD3—bipolar disorder	4.97e-05	0.000444	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HTR2A—bipolar disorder	4.93e-05	0.000439	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—COMT—bipolar disorder	4.89e-05	0.000436	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—MAOA—bipolar disorder	4.86e-05	0.000433	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD4—bipolar disorder	4.83e-05	0.000431	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—COMT—bipolar disorder	4.83e-05	0.00043	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—bipolar disorder	4.77e-05	0.000425	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DGKH—bipolar disorder	4.73e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR1A—bipolar disorder	4.7e-05	0.000419	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD5—bipolar disorder	4.68e-05	0.000417	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TAC1—bipolar disorder	4.63e-05	0.000413	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RGS4—bipolar disorder	4.59e-05	0.000409	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD1—bipolar disorder	4.54e-05	0.000405	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2C—bipolar disorder	4.54e-05	0.000405	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD2—bipolar disorder	4.5e-05	0.000401	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TRPC3—bipolar disorder	4.5e-05	0.000401	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRG1—bipolar disorder	4.49e-05	0.0004	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ADCY2—bipolar disorder	4.45e-05	0.000397	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C4—bipolar disorder	4.43e-05	0.000395	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD3—bipolar disorder	4.4e-05	0.000392	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD5—bipolar disorder	4.32e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADM—bipolar disorder	4.29e-05	0.000383	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—bipolar disorder	4.28e-05	0.000382	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR1A—bipolar disorder	4.27e-05	0.000381	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD4—bipolar disorder	4.27e-05	0.000381	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RGS4—bipolar disorder	4.24e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TAC1—bipolar disorder	4.2e-05	0.000375	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—IMPA2—bipolar disorder	4.19e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PDE4B—bipolar disorder	4.18e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TSHB—bipolar disorder	4.18e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TACR1—bipolar disorder	4.18e-05	0.000373	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—COMT—bipolar disorder	4.14e-05	0.00037	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2C—bipolar disorder	4.12e-05	0.000368	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD1—bipolar disorder	4.12e-05	0.000368	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—MAOA—bipolar disorder	4.12e-05	0.000367	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—COMT—bipolar disorder	4.09e-05	0.000364	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TRPC3—bipolar disorder	4.08e-05	0.000364	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR2A—bipolar disorder	4.05e-05	0.000361	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADCY2—bipolar disorder	4.02e-05	0.000358	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD3—bipolar disorder	3.99e-05	0.000356	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—NR1D1—bipolar disorder	3.98e-05	0.000355	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD2—bipolar disorder	3.98e-05	0.000354	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—POMC—bipolar disorder	3.94e-05	0.000351	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TRPC3—bipolar disorder	3.91e-05	0.000348	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADM—bipolar disorder	3.9e-05	0.000347	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD4—bipolar disorder	3.88e-05	0.000346	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—bipolar disorder	3.81e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TSHB—bipolar disorder	3.8e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PDE4B—bipolar disorder	3.8e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TACR1—bipolar disorder	3.8e-05	0.000339	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKR1C4—bipolar disorder	3.78e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADM—bipolar disorder	3.73e-05	0.000332	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADCY2—bipolar disorder	3.65e-05	0.000325	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PDE4B—bipolar disorder	3.63e-05	0.000324	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TACR1—bipolar disorder	3.63e-05	0.000324	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TSHB—bipolar disorder	3.63e-05	0.000324	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR2A—bipolar disorder	3.63e-05	0.000324	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD2—bipolar disorder	3.61e-05	0.000322	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TRPC3—bipolar disorder	3.55e-05	0.000316	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IMPA2—bipolar disorder	3.55e-05	0.000316	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DGKH—bipolar disorder	3.48e-05	0.00031	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR1A—bipolar disorder	3.46e-05	0.000309	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TAC1—bipolar disorder	3.41e-05	0.000304	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADM—bipolar disorder	3.38e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD1—bipolar disorder	3.34e-05	0.000298	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—bipolar disorder	3.3e-05	0.000295	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TSHB—bipolar disorder	3.3e-05	0.000294	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PDE4B—bipolar disorder	3.3e-05	0.000294	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TACR1—bipolar disorder	3.3e-05	0.000294	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKR1C4—bipolar disorder	3.28e-05	0.000293	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRPC3—bipolar disorder	3.28e-05	0.000292	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GSK3B—bipolar disorder	3.26e-05	0.000291	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD3—bipolar disorder	3.24e-05	0.000289	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—POMC—bipolar disorder	3.23e-05	0.000288	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—INS—bipolar disorder	3.22e-05	0.000287	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD5—bipolar disorder	3.18e-05	0.000284	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—POMC—bipolar disorder	3.16e-05	0.000282	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR1A—bipolar disorder	3.14e-05	0.00028	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD4—bipolar disorder	3.14e-05	0.00028	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADM—bipolar disorder	3.13e-05	0.000279	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RGS4—bipolar disorder	3.12e-05	0.000278	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TAC1—bipolar disorder	3.1e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TSHB—bipolar disorder	3.05e-05	0.000272	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDE4B—bipolar disorder	3.05e-05	0.000272	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TACR1—bipolar disorder	3.05e-05	0.000272	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD1—bipolar disorder	3.04e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DGKH—bipolar disorder	3.02e-05	0.00027	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HTR1A—bipolar disorder	3.01e-05	0.000268	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TAC1—bipolar disorder	2.96e-05	0.000264	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADCY2—bipolar disorder	2.96e-05	0.000264	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD3—bipolar disorder	2.94e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD2—bipolar disorder	2.93e-05	0.000261	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HTR2C—bipolar disorder	2.9e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD1—bipolar disorder	2.9e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—POMC—bipolar disorder	2.9e-05	0.000258	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD4—bipolar disorder	2.85e-05	0.000254	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—IMPA1—bipolar disorder	2.83e-05	0.000252	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD3—bipolar disorder	2.81e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2A—bipolar disorder	2.78e-05	0.000248	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD5—bipolar disorder	2.76e-05	0.000247	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HTR1A—bipolar disorder	2.73e-05	0.000243	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD4—bipolar disorder	2.73e-05	0.000243	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RGS4—bipolar disorder	2.71e-05	0.000242	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CLOCK—bipolar disorder	2.7e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TAC1—bipolar disorder	2.69e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADCY2—bipolar disorder	2.69e-05	0.00024	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—bipolar disorder	2.68e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD2—bipolar disorder	2.66e-05	0.000237	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD1—bipolar disorder	2.64e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HTR2C—bipolar disorder	2.64e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADCY2—bipolar disorder	2.57e-05	0.000229	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD3—bipolar disorder	2.55e-05	0.000228	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD2—bipolar disorder	2.54e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2A—bipolar disorder	2.53e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR1A—bipolar disorder	2.52e-05	0.000225	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—bipolar disorder	2.52e-05	0.000224	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TAC1—bipolar disorder	2.48e-05	0.000221	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD4—bipolar disorder	2.48e-05	0.000221	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2C—bipolar disorder	2.44e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD1—bipolar disorder	2.44e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRPC3—bipolar disorder	2.41e-05	0.000215	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NDUFV2—bipolar disorder	2.4e-05	0.000214	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IMPA1—bipolar disorder	2.4e-05	0.000214	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK2—bipolar disorder	2.37e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD3—bipolar disorder	2.36e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GSK3A—bipolar disorder	2.35e-05	0.000209	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—bipolar disorder	2.34e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADCY2—bipolar disorder	2.33e-05	0.000208	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1C4—bipolar disorder	2.33e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD2—bipolar disorder	2.31e-05	0.000206	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADM—bipolar disorder	2.3e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD4—bipolar disorder	2.29e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSHB—bipolar disorder	2.24e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDE4B—bipolar disorder	2.24e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TACR1—bipolar disorder	2.24e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—bipolar disorder	2.22e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADCY2—bipolar disorder	2.16e-05	0.000192	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TCF7L2—bipolar disorder	2.15e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD2—bipolar disorder	2.13e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRPC3—bipolar disorder	2.1e-05	0.000187	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NR1D1—bipolar disorder	2.09e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—bipolar disorder	2.05e-05	0.000183	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NDUFV2—bipolar disorder	2.04e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—bipolar disorder	2.02e-05	0.00018	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCAN—bipolar disorder	2e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADM—bipolar disorder	2e-05	0.000178	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1C4—bipolar disorder	1.97e-05	0.000176	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A3—bipolar disorder	1.96e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDE4B—bipolar disorder	1.95e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSHB—bipolar disorder	1.95e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TACR1—bipolar disorder	1.95e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NTRK1—bipolar disorder	1.93e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—S100B—bipolar disorder	1.88e-05	0.000167	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—bipolar disorder	1.86e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR1A—bipolar disorder	1.86e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TAC1—bipolar disorder	1.83e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD1—bipolar disorder	1.79e-05	0.00016	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NR1D1—bipolar disorder	1.77e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK2—bipolar disorder	1.74e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD3—bipolar disorder	1.74e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GSK3A—bipolar disorder	1.73e-05	0.000154	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCAN—bipolar disorder	1.69e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD4—bipolar disorder	1.69e-05	0.00015	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A3—bipolar disorder	1.66e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRG1—bipolar disorder	1.66e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—bipolar disorder	1.64e-05	0.000146	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HTR1A—bipolar disorder	1.61e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TAC1—bipolar disorder	1.59e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADCY2—bipolar disorder	1.59e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TCF7L2—bipolar disorder	1.58e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD2—bipolar disorder	1.57e-05	0.00014	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HTR2C—bipolar disorder	1.56e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD1—bipolar disorder	1.56e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK2—bipolar disorder	1.51e-05	0.000135	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD3—bipolar disorder	1.51e-05	0.000134	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GSK3A—bipolar disorder	1.5e-05	0.000134	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—bipolar disorder	1.49e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—bipolar disorder	1.49e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD4—bipolar disorder	1.46e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—bipolar disorder	1.42e-05	0.000127	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK1—bipolar disorder	1.42e-05	0.000127	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CLOCK—bipolar disorder	1.42e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—S100B—bipolar disorder	1.38e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TSHB—bipolar disorder	1.38e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPH2—bipolar disorder	1.38e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CACNB2—bipolar disorder	1.38e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADCY2—bipolar disorder	1.38e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TCF7L2—bipolar disorder	1.37e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD2—bipolar disorder	1.36e-05	0.000122	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—DPYD—bipolar disorder	1.36e-05	0.000121	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—bipolar disorder	1.29e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CACNA1C—bipolar disorder	1.26e-05	0.000113	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK1—bipolar disorder	1.23e-05	0.00011	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3C2A—bipolar disorder	1.23e-05	0.00011	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRG1—bipolar disorder	1.22e-05	0.000109	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GSK3B—bipolar disorder	1.2e-05	0.000107	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CLOCK—bipolar disorder	1.2e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S100B—bipolar disorder	1.2e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—bipolar disorder	1.19e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—bipolar disorder	1.19e-05	0.000106	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPH2—bipolar disorder	1.17e-05	0.000104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TSHB—bipolar disorder	1.17e-05	0.000104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CACNB2—bipolar disorder	1.17e-05	0.000104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—DPYD—bipolar disorder	1.15e-05	0.000103	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SNAP25—bipolar disorder	1.1e-05	9.84e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—bipolar disorder	1.1e-05	9.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CACNA1C—bipolar disorder	1.07e-05	9.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRG1—bipolar disorder	1.06e-05	9.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3C2A—bipolar disorder	1.04e-05	9.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—bipolar disorder	1.03e-05	9.17e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADCY2—bipolar disorder	9.77e-06	8.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SNAP25—bipolar disorder	9.35e-06	8.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GSK3B—bipolar disorder	8.86e-06	7.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—bipolar disorder	8.79e-06	7.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—bipolar disorder	8.74e-06	7.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COMT—bipolar disorder	8.37e-06	7.46e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MAOA—bipolar disorder	8.31e-06	7.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADCY2—bipolar disorder	8.28e-06	7.38e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GSK3B—bipolar disorder	7.69e-06	6.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—bipolar disorder	7.63e-06	6.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—bipolar disorder	7.59e-06	6.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COMT—bipolar disorder	7.09e-06	6.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MAOA—bipolar disorder	7.04e-06	6.28e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—bipolar disorder	6.76e-06	6.03e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—bipolar disorder	5.73e-06	5.11e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—bipolar disorder	5.41e-06	4.82e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—bipolar disorder	5.38e-06	4.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—bipolar disorder	4.58e-06	4.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—bipolar disorder	4.56e-06	4.06e-05	CbGpPWpGaD
